Clinical Trial Update: Macitentan to Prevent PRVO [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating macitentan to prevent pulmonary vascular events has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism

Drugs mentioned

• Macitentan (macitentan)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Pulmonary Embolism | Phase 3 | Status: WITHDRAWN